References
- Carlsson R M, Claesson B A, Iwarson S, Lagergard T, Käyhty H. Antibodies against Haemophilus influenzae type b and tetanus in infants after subcutaneous vaccination with PRP-T/diphtheria, or PRP-OMP/diphtheria-tetanus vaccines. Pediatr Infect Dis J 1994; 13: 27–33
- Mäkelä P H, Peltola H, Käyhty H, Jousimies H, Pettay O, Ruoslahti E, Sivonen A, Renkonen O V. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977; 136: S43–S50
- Manclark C R, Meade B D, Burstyn D B. Serological response to Bordetella pertussis. Manual of clinical laboratory immunology, 3rd edn., N R Rose, H Friedman, J L Fahey. American Society for Microbiology, Washington DC 1986; 388–394
- Käyhty H, Peltola H, Karanko V, Mäkelä P H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147: 1100
- Bizzini B. Tetanus. Bacterial vaccines, Bermanier. Academic Press, Orlando, FL 1984; 37–68
- Claesson B A, Schneerson R, Lagergård T, Trollfors B, Taranger J, Johansson J, Bryla D, Robbins J B. Persistence of serum antibodies elicited by Haemophilus influenzae type b tetanus toxoid-conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age. Pediatr Infect Dis J 1991; 10: 560–564
- Advisory Committee on Immunization Practices update. Report of Pedvax-HIB® lots with questionable immunogenicity. MMWR 1992; 41: 878–879
- Marwick C. Additional dose urged for some receiving Haemophilus influenzae vaccine in early '90s. JAMA 1992; 268: 3287
- Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994; 22: 397–402
- Claesson B A, Trollfors B, Anderson P W, Johansson J, Taranger J, Schneerson R, Robbins J B. Serum antibodies in 6–year-old children vaccinated in infancy with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 1996; 15: 170–172
- Kurikka S, Käyhty H, Saarinen L, Rönnberg P R, Eskola J, Mäkelä P H. Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. J Infect Dis 1995; 172: 1268–1272
- Calandra G B, Lukacs L J, Jonas L C, Santosham M, Ward J I, Greenberg D P, Daum R S, Matthews H, Vella P P, Ryan J L. Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses. Vaccine 1993; 11: S58–S62
- Rothstein E P, Madore D V, Long S S, Pennridge Pediatric Associates members. Antibody persistence four years after primary immunization of infants and toddlers with Haemophilus influenzae type b CRM197 conjugate vaccine. J Pediatr 1991; 119: 655–657, other
- Claesson B A, Trollfors B, Lagergård T, Taranger J, Bryla D, Otterman G, Cramton T, Yang Y, Reimer C B, Robbins J B, Schneerson R. Clinical and immunologic responses to the capsular polysaccharide of Haemophilus influenzae typ b alone or conjugated to tetanus toxoid in 18- to 23-month-old children. J Pediatr 1988; 112: 695–702
- Granoff D M, Rathore M H, Holmes S J, Granoff P D, Lucas A H. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 1993; 11: S46–S51